Peringatan Keamanan

LD50=785 mg/kg (orally in rats)

Procarbazine

DB01168

small molecule approved investigational

Deskripsi

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Struktur Molekul 2D

Berat 221.2988
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 10 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Procarbazine is rapidly and completely absorbed.

Metabolisme

Procarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Ingesting alcohol may potentiate the CNS depressant effects of procarbazine and may precipitate a disulfiram-like-reaction (nausea, flushing).
  • 2. Avoid tyramine-containing foods and supplements. Foods that contain tyramine include yogurt, aged cheese, ripe bananas, wine, and sourdough bread.

Interaksi Obat

1585 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Procarbazine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Procarbazine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Procarbazine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Procarbazine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Procarbazine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Procarbazine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Procarbazine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Procarbazine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Procarbazine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Procarbazine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Procarbazine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Procarbazine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Procarbazine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Procarbazine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Procarbazine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Procarbazine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Procarbazine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Procarbazine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Procarbazine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Procarbazine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Procarbazine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Procarbazine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Procarbazine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Procarbazine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Procarbazine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Procarbazine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Procarbazine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Procarbazine.
Cladribine Procarbazine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Procarbazine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Procarbazine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Procarbazine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Procarbazine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Procarbazine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Procarbazine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Procarbazine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Procarbazine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Procarbazine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Procarbazine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Procarbazine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Procarbazine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Procarbazine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Procarbazine.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Procarbazine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Procarbazine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Procarbazine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Procarbazine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Procarbazine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Procarbazine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Procarbazine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Procarbazine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Procarbazine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Procarbazine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Procarbazine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Procarbazine.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Procarbazine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Procarbazine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Procarbazine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Procarbazine.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Procarbazine.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Procarbazine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Procarbazine.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Procarbazine.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Procarbazine.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Procarbazine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Procarbazine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Procarbazine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Procarbazine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Procarbazine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Procarbazine.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Procarbazine.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Procarbazine.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Procarbazine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Procarbazine.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Procarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Procarbazine.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Procarbazine.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Procarbazine.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Procarbazine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Procarbazine.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Procarbazine.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Procarbazine.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Procarbazine.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Procarbazine.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Procarbazine.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Procarbazine.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Procarbazine.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Procarbazine.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Procarbazine.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Procarbazine.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Procarbazine.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Procarbazine.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Procarbazine.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Procarbazine.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Procarbazine.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Procarbazine.

Target Protein

Monoamine oxidase MAOA
DNA

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 3 • International brands: 2
Produk
  • Matulane
    Capsule • 50 mg/1 • Oral • US • Approved
  • Matulane
    Capsule • 50 mg/1 • Oral • US • Approved
  • Matulane
    Capsule • 50 mg • Oral • Canada • Approved
International Brands
  • Indicarb
  • Natulan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul